89 results on '"Dufrost V"'
Search Results
2. Développement d’un examen clinique objectif structuré (ECOS) pour évaluer les compétences des étudiants en médecine vasculaire
- Author
-
Risse, J., Busato, T., Dufrost, V., Perri, M., Zuily, S., and Wahl, D.
- Published
- 2017
- Full Text
- View/download PDF
3. Artériopathies non athéromateuses : orientations diagnostiques et prise en charge
- Author
-
Wahl, D., Risse, J., Dufrost, V., Busato, T., and Zuily, S.
- Published
- 2017
- Full Text
- View/download PDF
4. Épidémiologie, histoire naturelle, diagnostic et prise en charge de la thrombose de la veine ovarienne : revue systématique de la littérature et méta-analyse
- Author
-
Monnet, M., primary, Dufrost, V., additional, Zuily-Lamy, C., additional, Foret, T., additional, Fijean, A., additional, Bertholdt, C., additional, Wahl, D., additional, Morel, O., additional, Agopiantz, M., additional, and Zuily, S., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Facteurs précipitants la survenue d’un syndrome catastrophique des antiphospholipides : étude du rôle du traitement anticoagulant
- Author
-
Stammler, R., primary, Nguyen, Y., additional, Yelnik, C., additional, Le Guern, V., additional, Lambert, M., additional, Paule, R., additional, Mouthon, L., additional, Dupré, A., additional, Ackermann, F., additional, Dufrost, V., additional, Godeau, B., additional, Leroux, G., additional, Benhamou, Y., additional, Lazaro, E., additional, Daugas, E., additional, Bezanahary, H., additional, Mekinian, A., additional, Piette, J.C., additional, Morel, N., additional, and Costedoat-Chalumeau, N., additional
- Published
- 2022
- Full Text
- View/download PDF
6. Atteintes cutanées au cours du syndrome catastrophique des antiphospholipides – Cohorte descriptive multicentrique de 65 patients
- Author
-
Dupré, A., primary, Morel, N., additional, Yelnik, C., additional, Moguelet, P., additional, Le Guern, V., additional, Stammler, R., additional, Nguyen, Y., additional, Paule, R., additional, Dufrost, V., additional, Ackermann, F., additional, Benhamou, Y., additional, Godeau, B., additional, Lambert, M., additional, Duffau, P., additional, Mékinian, A., additional, Saadoun, D., additional, Mouthon, L., additional, Hachulla, E., additional, Maillard, H., additional, Levesque, H., additional, Morell-Dubois, S., additional, Leroux, G., additional, Piette, J.C., additional, Chasset, F., additional, and Costedoat-Chalumeau, N., additional
- Published
- 2022
- Full Text
- View/download PDF
7. 150 - La cinétique des D-dimères pendant l'hospitalisation est un facteur pronostique majeur de décès chez les patients hospitalisés pour COVID-19
- Author
-
Julien, M., primary, Omorou, A., additional, Dufrost, V., additional, Foret, T., additional, Salignac, S., additional, Broseus, J., additional, Wahl, D., additional, Eschwège, V., additional, and Zuily, S., additional
- Published
- 2022
- Full Text
- View/download PDF
8. Erratum to: “Microvascular manifestations revealing vaccine-induced thrombotic thrombocytopenia after COVID-19 vaccination” [J. Med. Vasc. 47 (2022) 36–38]
- Author
-
Noyé, M., primary, Sauvage, A., additional, Toussaint, M., additional, Benoit, R., additional, Foret, T., additional, Lagrange, J., additional, Dufrost, V., additional, Regnault, V., additional, Zuily, S., additional, and Wahl, D.G., additional
- Published
- 2022
- Full Text
- View/download PDF
9. Syndrome des antiphospholipides après 65 ans : étude comparative rétrospective des caractéristiques clinicobiologiques et des récidives thrombotiques
- Author
-
Crosnier, C., primary, Dufrost, V., additional, Audrain, M., additional, Hemont, C., additional, Agard, C., additional, Connault, J., additional, Artifoni, M., additional, Fouassier, M., additional, Hamidou, M., additional, Guédon, A.F., additional, Zuily, S., additional, and Espitia, O., additional
- Published
- 2022
- Full Text
- View/download PDF
10. La cinétique des D-dimères pendant l'hospitalisation est un facteur pronostique majeur de décès chez les patients hospitalisés pour COVID-19
- Author
-
Julien, M., primary, Omorou, Y., additional, Dufrost, V., additional, Foret, T., additional, Broseus, J., additional, Salignac, S., additional, Wahl, D., additional, Eschwège, V., additional, and Zuily, S., additional
- Published
- 2022
- Full Text
- View/download PDF
11. Microvascular manifestations revealing vaccine-induced thrombotic thrombocytopenia after COVID-19 vaccination
- Author
-
Noyé, M., Sauvage, A., Toussaint, M., Benoit, R., Foret, T., Lagrange, J., Dufrost, V., Regnault, V., Zuily, S., and Wahl, D.G.
- Published
- 2022
- Full Text
- View/download PDF
12. Risque de livedo associé aux anticorps antiphospholipides chez les patients atteints de lupus érythémateux systémique : revue systématique et méta-analyse
- Author
-
Loiseau, P., primary, Foret, T., additional, DeFilippis, E.M., additional, Risse, J., additional, Etienne, A. Dor, additional, Dufrost, V., additional, Moulinet, T., additional, Erkan, D., additional, Devilliers, H., additional, Wahl, D., additional, and Zuily, S., additional
- Published
- 2022
- Full Text
- View/download PDF
13. Anévrysmes infectieux de l’aorte abdominale. Diagnostic
- Author
-
Wahl, D., primary, Zieminski, P., additional, Zuily, S., additional, and Dufrost, V., additional
- Published
- 2021
- Full Text
- View/download PDF
14. Atteintes cutanées au cours du syndrome catastrophique des antiphospholipides : série de 65 patients
- Author
-
Dupré, A., primary, Morel, N., additional, Moguelet, P., additional, Stammler, R., additional, Yelnik, C., additional, Dufrost, V., additional, Ackermann, F., additional, Benhamou, Y., additional, Godeau, B., additional, Lambert, M., additional, Duffau, P., additional, Mekinian, A., additional, Saadoun, D., additional, Hachulla, E., additional, Maillard, H., additional, Levesque, H., additional, Morell-Dubois, S., additional, Piette, J.C., additional, Chasset, F., additional, and Costedoat-Chalumeau, N., additional
- Published
- 2021
- Full Text
- View/download PDF
15. Syndrome des antiphospholipides et anticoagulants oraux directs
- Author
-
Wahl, D., primary, Zuily, S., additional, and Dufrost, V., additional
- Published
- 2020
- Full Text
- View/download PDF
16. Anévrysmes infectieux de l’aorte abdominale. Diagnostic
- Author
-
Wahl, D., primary, Zieminski, P., additional, Zuily, S., additional, and Dufrost, V., additional
- Published
- 2020
- Full Text
- View/download PDF
17. Syndrome catastrophique des antiphospholipides : une étude rétrospective descriptive multicentrique
- Author
-
Stammler, R., primary, Morel, N., additional, Lambert, M., additional, Godeau, B., additional, Yelnik, C., additional, Dufrost, V., additional, Benhamou, Y., additional, Le Guern, V., additional, Amoura, Z., additional, Leroux, G., additional, Piette, J.C., additional, and Costedoat-Chalumeau, N., additional
- Published
- 2019
- Full Text
- View/download PDF
18. Augmentation du risque thrombotique chez les patients SAPL traités par anticoagulants oraux directs : résultats d’une méta-analyse internationale sur données individuelles
- Author
-
Dufrost, V., primary, Reshetnyak, T., additional, Satybaldyeva, M., additional, Du, Y., additional, Yan, X.-X., additional, Salta, S., additional, Gerotziafas, G., additional, Jing, Z.-C., additional, Elalamy, I., additional, Zuily, S., additional, and Wah, D., additional
- Published
- 2019
- Full Text
- View/download PDF
19. Epidemiology, natural history, diagnosis, and management of ovarian vein thrombosis: a scoping review.
- Author
-
Monnet M, Dufrost V, Wahl D, Morel O, Agopiantz M, and Zuily S
- Subjects
- Humans, Female, Adult, Risk Factors, Middle Aged, Treatment Outcome, Venous Thrombosis diagnosis, Venous Thrombosis epidemiology, Venous Thrombosis therapy, Venous Thrombosis diagnostic imaging, Anticoagulants therapeutic use, Ovary blood supply, Ovary diagnostic imaging
- Abstract
Ovarian vein thrombosis (OVT) is a rare but potentially serious condition. We conducted a scoping review of published data to provide a better understanding of OVT management. MEDLINE and Cochrane databases were searched. The eligibility criterion was original articles including women with OVT until May 2024. Quantitative data were pooled via Comprehensive Meta-Analysis software (Biostat, Inc). Quality of the primary studies was assessed via the Newcastle‒Ottawa Scale. Out of 1007 identified records, 19 primary studies including 1128 patients were selected. Mean age at OVT diagnosis was 37 years old. Frequency of OVT depended on the clinical situation: cancer (37%) and postpartum (0.06%), including cesarean (0.19%), or persistent fever despite antibiotics (23%). Magnetic resonance imaging was associated with the best diagnostic performance, followed by computed tomography. Pulmonary embolism and extension to the iliac vein, inferior vena cava, or left renal vein occurred in 6.5%, 5.9%, 10.3%, and 9.6% of patients, respectively. Among anticoagulants, low-molecular-height heparin with/without oral anticoagulant was preferred for 3 to 6 months. Among the women tested, thrombophilia was present in 18% of the patients. Recanalization, recurrent thrombosis, or major bleeding occurred in 70%, 8%, and 2% of patients, respectively. The majority of studies had poor evidence. This scoping review provides a comprehensive evaluation of available data. Frequency of OVT depends on the clinical setting. Physicians should be aware of OVT in postpartum women with persistent fever despite the use of antibiotics. OVT belongs to the spectrum of venous thromboembolism and should be considered both in puerperal settings and in cancer patients., Competing Interests: Declaration of competing interests There are no competing interests to disclose., (Copyright © 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
20. Thrombin Generation Assay in Antiphospholipid Antibodies Positive Subjects as a Personalized Thrombotic Risk Assessment: State of the Art and Perspectives.
- Author
-
Foret T, Dufrost V, Lagrange J, Costa P, Mourey G, Lecompte T, Magy-Bertrand N, Regnault V, Zuily S, and Wahl D
- Subjects
- Humans, Risk Assessment methods, Activated Protein C Resistance, Blood Coagulation Tests methods, Precision Medicine methods, Thrombosis etiology, Antiphospholipid Syndrome immunology, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome diagnosis, Antiphospholipid Syndrome blood, Thrombin metabolism, Antibodies, Antiphospholipid blood, Antibodies, Antiphospholipid immunology
- Abstract
Purpose of the Review: Thrombotic risk assessment in antiphospholipid positive (aPL +) subjects is a major challenge, and the study of in vitro thrombin generation (thrombin generation assays (TGA)) could provide useful information. Activated protein C (APC) sensitivity is involved in thrombotic events in antiphospholipid syndrome patients. We summarized methods used to assess APC sensitivity with TGA and evaluated the prognostic role of APC resistance through literature search., Recent Findings: APC resistance induced by aPL is a complex pathway. Several cross-sectional studies assessed APC sensitivity to understand thrombotic event mechanisms in aPL + subjects. Only one prospective cohort had investigated the prognostic impact of APC resistance in aPL + subjects, with a positive and significant correlation between APC sensitivity and the risk of thrombosis during the follow up (hazard ratio, 6.07 [95% CI, 1.69-21.87]). APC resistance assessed with TGA could be associated with thrombotic events in aPL + subjects., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
21. Determination of four homogeneous subgroups of patients with antiphospholipid syndrome: a cluster analysis based on 509 cases.
- Author
-
Nguyen Y, Yelnik CM, Morel N, Paule R, Stammler R, Plaçais L, Sacré K, Godeau B, Maillard H, Launay D, Morell-Dubois S, Dupré A, Lefèvre G, Devloo C, Dufrost V, Benhamou Y, Levesque H, Leroux G, Piette JC, Mouthon L, Hachulla É, Lambert M, Le Guern V, and Costedoat-Chalumeau N
- Subjects
- Pregnancy, Female, Male, Humans, Retrospective Studies, Antiphospholipid Syndrome complications, Venous Thromboembolism, Thrombosis, Kidney Diseases
- Abstract
Objective: APS is a heterogeneous disease with different phenotypes. Using an unsupervised hierarchical cluster analysis, we aimed to determine distinct homogeneous phenotypes among APS patients., Methods: We performed an observational, retrospective study of APS patients enrolled in the French multicentre 'APS and SLE' registry who met the Sydney classification criteria. The clustering process involved an unsupervised multiple correspondence analysis followed by a hierarchical ascendant clustering analysis; it used 27 variables selected to cover a broad range of APS clinical and laboratory manifestations., Results: These analyses included 509 patients, mainly women (77.8%). Mean (s.d.) age at APS diagnosis was 36.2 (14.6) years, and mean follow-up since diagnosis 10.3 (8.5) years. This hierarchical classification cluster analysis yielded four homogeneous groups of patients: cluster 1, mostly with venous thromboembolism without any associated autoimmune disease; cluster 2, older, lowest proportion of women, history of arterial events, and/or with migraines, arterial hypertension, diabetes mellitus, or dyslipidaemia; cluster 3, younger, highest proportion of women, associated SLE or other autoimmune diseases, and a history of venous thromboembolism or pregnancy morbidity; and cluster 4, mainly with a history of catastrophic antiphospholipid syndrome, aPL-associated nephropathy, and pregnancy morbidity, with frequent triple positivity and more deaths (16.7%)., Conclusions: Our study applied an unsupervised clustering method to distinguish four homogeneous APS patient subgroups that were predominantly venous; arterial; associated with SLE or another autoimmune disease; and arterial microthrombotic. Heterogeneous pathophysiological mechanisms may explain these findings., (© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
22. Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study.
- Author
-
Mekinian A, Biard L, Lorenzo D, Novikov PI, Salvarani C, Espitia O, Sciascia S, Michaud M, Lambert M, Hernández-Rodríguez J, Schleinitz N, Awisat A, Puechal X, Aouba A, Munoz Pons H, Smitienko I, Gaultier JB, Edwige LM, Benhamou Y, Perlat A, Jego P, Goulenok T, Sacre K, Lioger B, Hassold N, Broner J, Dufrost V, Sené T, Seguier J, Maurier F, Berthier S, Belot A, Frikha F, Denis G, Audemard-Verger A, Koné-Paut I, Humbert S, Woaye-Hune P, Tomelleri A, Baldissera EM, Kuwana M, Lo Gullo A, Mukuchyan V, Dellal A, Gaches F, Zeminsky P, Galli E, Alvarado M, Boiardi L, Muratore F, Vautier M, Campochiaro C, Moiseev S, Vieira M, Cacoub P, Fain O, and Saadoun D
- Subjects
- Humans, Adult, Retrospective Studies, Treatment Outcome, Takayasu Arteritis diagnosis, Takayasu Arteritis drug therapy, Antirheumatic Agents therapeutic use
- Abstract
Objectives: In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients., Methods: We conducted a retrospective multicentre study in referral centres from France, Italy, Spain, Armenia, Israel, Japan, Tunisia and Russia regarding biological-targeted therapies in TAK, since January 2017 to September 2019., Results: A total of 109 TAK patients received at least 3 months tocilizumab therapy and were included in this study. Among them, 91 and 18 patients received intravenous and SC tocilizumab, respectively. A complete response (NIH <2 with less than 7.5 mg/day of prednisone) at 6 months was evidenced in 69% of TAK patients, of whom 57 (70%) and 11 (69%) patients were on intravenous and SC tocilizumab, respectively (p=0.95). The factors associated with complete response to tocilizumab at 6 months in multivariate analysis, only age <30 years (OR 2.85, 95% CI 1.14 to 7.12; p=0.027) and time between TAK diagnosis and tocilizumab initiation (OR 1.18, 95% CI 1.02 to 1.36; p=0.034). During the median follow-up of 30.1 months (0.4; 105.8) and 10.8 (0.1; 46.4) (p<0.0001) in patients who received tocilizumab in intravenous and SC forms, respectively, the risk of relapse was significantly higher in TAK patients on SC tocilizumab (HR=2.55, 95% CI 1.08 to 6.02; p=0.033). The overall cumulative incidence of relapse at 12 months in TAK patients was at 13.7% (95% CI 7.6% to 21.5%), with 10.3% (95% CI 4.8% to 18.4%) for those on intravenous tocilizumab vs 30.9% (95% CI 10.5% to 54.2%) for patients receiving SC tocilizumab. Adverse events occurred in 14 (15%) patients on intravenous route and in 2 (11%) on SC tocilizumab., Conclusion: In this study, we confirm that tocilizumab is effective in TAK, with complete remission being achieving by 70% of disease-modifying antirheumatic drugs-refractory TAK patients at 6 months., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
23. Precipitating factors of catastrophic antiphospholipid syndrome: the role of anticoagulant treatment in a series of 112 patients.
- Author
-
Stammler R, Nguyen Y, Yelnik C, Le Guern V, Lambert M, Paule R, Hachulla E, Mouthon L, Dupré A, Ackermann F, Dufrost V, Wahl D, Godeau B, Leroux G, Benhamou Y, Lazaro E, Daugas E, Bezanahary H, Mekinian A, Piette JC, Morel N, and Costedoat-Chalumeau N
- Subjects
- Pregnancy, Female, Male, Humans, Anticoagulants adverse effects, Precipitating Factors, Retrospective Studies, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome diagnosis, Antiphospholipid Syndrome drug therapy, Lupus Erythematosus, Systemic
- Abstract
Background: The prevention of catastrophic antiphospholipid syndrome (CAPS), a rare complication of antiphospholipid syndrome (APS), is a major goal., Objectives: We analyzed its precipitating factors, focusing on anticoagulation immediately before CAPS episodes., Methods: We retrospectively analyzed patients in the French multicenter APS/systemic lupus erythematosus database with at least 1 CAPS episode. Then we compared each patient with known APS before CAPS with 2 patients with non-CAPS APS matched for age, sex, center, and APS phenotype., Results: We included 112 patients with CAPS (70% women; mean age, 43 ± 15 years). At least 1 standard precipitating factor of CAPS was observed for 67 patients (64%), which were mainly infections (n = 28, 27%), pregnancy (n = 23, 22%), and surgery (n = 16, 15%). Before the CAPS episode, 67 (60%) patients already had a diagnosis of APS. Of the 61 treated with anticoagulants, 32 (48%) received vitamin K antagonists (VKAs), 23 (34%) heparin, and 2 (3%) a direct oral anticoagulant. They were less likely than their matched patients with APS without CAPS to receive VKA (48% vs 66%, p = .001). Among those treated with VKA, 72% had a subtherapeutic international normalized ratio (ie, <2) versus 28% in patients with APS without CAPS (p < .001). Finally, excluding pregnant patients (n = 14) for whom we could not differentiate the effect of treatment from that of pregnancy, we were left with 47 cases, 32 (68%) of whom had recently begun a direct oral anticoagulant, planned bridging therapy, or had VKA treatment with international normalized ratio <2., Conclusion: These results strongly suggest that suboptimal anticoagulation management can trigger CAPS in patients with thrombotic APS., Competing Interests: Declaration of competing interests There are no competing interests to disclose., (Copyright © 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
24. Circulating Endothelial Cells are Associated with Thromboembolic Events in Patients with Antiphospholipid Antibodies.
- Author
-
Foret T, Dufrost V, Heymonet M, Risse J, Faure GC, Louis H, Lagrange J, Lacolley P, Devreese K, Gibot S, Regnault V, Zuily S, and Wahl D
- Subjects
- Humans, Female, Adult, Middle Aged, Male, Endothelial Cells, Antibodies, Antiphospholipid, Obesity complications, Venous Thromboembolism complications, Lupus Erythematosus, Systemic, Antiphospholipid Syndrome complications, Thrombosis, Vascular Diseases
- Abstract
Background: Endothelial damage has been described in antiphospholipid antibody (aPL)-positive patients. However, it is uncertain whether circulating endothelial cells (CECs)-which are released when endothelial injury occurs-can be a marker of patients at high risk for thrombosis., Methods: Ninety-seven patients with aPL and/or systemic lupus erythematosus (SLE) were included. CECs were determined by an automated CellSearch system. We also assayed plasma levels of tissue factor-bearing extracellular vesicles (TF
+ /EVs) and soluble triggering receptor expressed on myeloid cells 1 (sTREM-1) as markers of endothelial dysfunction/damage., Results: Patients' mean age was 46.1 ± 13.9 years, 77 were women. Thirty-seven had SLE and 75 patients were suffering from antiphospholipid syndrome. Thirty-seven percent of patients presented a medical history of arterial thrombosis and 46% a history of venous thromboembolism (VTE). Thirteen patients had increased levels of CECs (>20/mL), with a mean CEC level of 48.3 ± 21.3 per mL. In univariate analysis, patients with obesity or medical history of myocardial infarction (MI), VTE, or nephropathy had a significant increased CEC level. In multivariate analysis, obesity (odds ratio [OR] = 6.07, 95% confidence interval [CI]: 1.42-25.94), VTE (OR = 7.59 [95% CI: 1.38-41.66]), and MI (OR = 5.5 [95% CI: 1.1-26.6)] were independently and significantly associated with elevated CECs. We also identified significant correlations between CECs and other markers of endothelial dysfunction: sTREM-1 and TF+ /EVs., Conclusion: This study demonstrated that endothelial injury assessed by the levels of CECs was associated with thromboembolic events in patients with aPL and/or autoimmune diseases., Competing Interests: None declared., (Thieme. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
25. Cutaneous Involvement in Catastrophic Antiphospholipid Syndrome in a Multicenter Cohort of 65 Patients.
- Author
-
Dupré A, Morel N, Yelnik C, Moguelet P, Le Guern V, Stammler R, Nguyen Y, Paule R, Dufrost V, Ackermann F, Benhamou Y, Godeau B, Lambert M, Duffau P, Mekinian A, Saadoun D, Mouthon L, Hachulla E, Maillard H, Levesque H, Morell-Dubois S, Leroux G, Piette JC, Chasset F, and Costedoat-Chalumeau N
- Subjects
- Humans, Female, Adult, Male, Retrospective Studies, Cohort Studies, Catastrophic Illness, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome epidemiology, Antiphospholipid Syndrome diagnosis, Lupus Erythematosus, Systemic pathology
- Abstract
Importance: Catastrophic antiphospholipid syndrome (CAPS) is a severe, rare complication of antiphospholipid syndrome (APS), but cutaneous involvement has not yet been adequately described., Objective: To describe cutaneous involvement during CAPS, its clinical and pathological features, and outcomes., Design, Setting, and Participants: This cohort study was a retrospective analysis of patients included in the French multicenter APS/systemic lupus erythematosus register (ClinicalTrials.gov: NCT02782039) by December 2020. All patients meeting the revised international classification criteria for CAPS were included, and patients with cutaneous manifestations were analyzed more specifically., Main Outcomes and Measures: Clinical and pathological data as well as course and outcome in patients with cutaneous involvement during CAPS were collected and compared with those in the register without cutaneous involvement., Results: Among 120 patients with at least 1 CAPS episode, the 65 (54%) with skin involvement (43 [66%] women; median [range] age, 31 [12-69] years) were analyzed. Catastrophic antiphospholipid syndrome was the first APS manifestation for 21 of 60 (35%) patients with available data. The main lesions were recent-onset or newly worsened livedo racemosa (n = 29, 45%), necrotic and/or ulcerated lesions (n = 27, 42%), subungual splinter hemorrhages (n = 19, 29%), apparent distal inflammatory edema (reddened and warm hands, feet, or face) (n = 15, 23%), and/or vascular purpura (n = 9, 14%). Sixteen biopsies performed during CAPS episodes were reviewed and showed microthrombi of dermal capillaries in 15 patients (94%). These lesions healed without sequelae in slightly more than 90% (58 of 64) of patients. Patients with cutaneous involvement showed a trend toward more frequent histologically proven CAPS (37% vs 24%, P = .16) than those without such involvement, while mortality did not differ significantly between the groups (respectively, 5% vs 9%, P = .47)., Conclusions and Relevance: In this cohort study, half the patients with CAPS showed cutaneous involvement, with a wide spectrum of clinical presentations, including distal inflammatory edema. Skin biopsies confirmed the diagnosis in all but 1 biopsied patient.
- Published
- 2023
- Full Text
- View/download PDF
26. Antiphospholipid syndrome in patients over 65 years: A comparative study of clinical and biological features and thrombotic relapses.
- Author
-
Masson C, An Nguyen TT, Dufrost V, Audrain M, Hémont C, Agard C, Artifoni M, Connault J, Fouassier M, Hamidou M, Guedon AF, Wahl D, Zuily S, and Espitia O
- Subjects
- Humans, Male, Aged, Female, Antibodies, Anticardiolipin, Lupus Coagulation Inhibitor, Recurrence, Immunoglobulin M, Antiphospholipid Syndrome diagnosis, Lupus Erythematosus, Systemic, Thrombosis, Venous Thrombosis epidemiology
- Abstract
Objective: The aim of the study was to describe clinical and biological characteristics and thrombotic relapses of patients diagnosed with antiphospholipid syndrome (APS) after the age of 65 years, in comparison with patients diagnosed with APS before 65., Methods: This retrospective multicenter study was performed to 2005 from 2017 and included patients diagnosed with APS after the age of 65 years, in accordance with Sydney criteria. We compared these patients with APS patients diagnosed before the age of 65 years, and with control thrombotic patients older than 65 years., Results: Fifty-eight APS patients over the age of 65 years were compared to 127 APS patients aged less than 65 and to 58 controls. In elderly APS versus younger APS, there was a male predominance (58.6% vs 36.2% p = .001); myocardial infarction and lower limb deep vein thrombosis (LLDVT) were more frequent in elderly, respectively, 12.1% versus 1.6% ( p = .005), and 44.8% versus 29.9% ( p = .048). Anticardiolipin antibody (aCL) IgM was more frequently found in old patients compared to younger patients (33.9% vs 18.1%, p = .02), contrary to lupus anticoagulant (LAC) (52.8% vs 66.9%, p = .02). Older patients were more often diagnosed with single positive APS (82.8% vs 59.8% p = .002). The thrombotic relapse free survival was lower in elderly APS patients ( p = .044) compared to younger APS. Elderly APS patients had more recurrent arterial and venous thrombosis ( p = .03) and had poorer overall survival ( p = .004) than elderly controls., Conclusion: In this study, APS was different in patients aged more than 65 years, with a male predominance and more myocardial infarctions and LLDVT at diagnosis. Single antiphopholipid positivity and aCL IgM were more frequent in older patients. Older patient with APS had more thrombotic recurrence during follow-up. Compared to elderly controls, elderly APS patients had more thrombosis recurrences and poorer survival.
- Published
- 2022
- Full Text
- View/download PDF
27. Risk of livedo with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis.
- Author
-
Loiseau P, Foret T, DeFilippis EM, Risse J, Etienne AD, Dufrost V, Moulinet T, Erkan D, Devilliers H, Wahl D, and Zuily S
- Subjects
- Humans, Antibodies, Antiphospholipid, Lupus Coagulation Inhibitor, beta 2-Glycoprotein I, Immunoglobulin G, Lupus Erythematosus, Systemic, Antiphospholipid Syndrome complications
- Abstract
Background: Livedo is a well-known skin condition in patients with systemic lupus erythematosus (SLE) which correspond to small vessels involvement. The influence of antiphospholipid antibodies (aPL) on the occurrence of livedo is controversial. The aim of our study was to estimate the risk of livedo associated with aPL in patients with SLE., Methods: We conducted a systematic review and meta-analysis of the literature from 1977 to 2021 to estimate the risk of livedo in SLE patients according to different aPL profiles. Data sources were PubMed, Embase, Cochrane Library, hand search, and reference lists of studies. Studies were selected if they included SLE patients with descriptions of the exposure to aPL and the outcome ( livedo ). Two independent investigators assessed study eligibility, quality, and extracted patient characteristics from each study as well as exposure (aPL) and outcome ( livedo ). Risk estimates were pooled using random effects models and sensitivity analyses. For all stages of the meta-analysis, we followed the PRISMA guidelines. PROSPERO registration number: CRD42015027377., Results: Of the 2,355 articles identified, 27 were included with a total of 4,810 SLE patients. The frequency of livedo was 25.5% in aPL-positive patients and 13.3% in aPL-negative patients. The overall Odds Ratio (OR) for livedo in aPL-positive patients compared to aPL-negative patients was 2.91 (95% CI; 2.17-3.90). The risk of livedo was significantly increased for most of aPL subtypes, including lupus anticoagulant (LA) (OR = 4.45 [95% CI; 2.21-8.94]), IgG anticardiolipin (OR = 3.95 [95% CI; 2.34-6.65]), and IgG anti-β
2 -glycoprotein 1 (OR = 3.49 [95% CI; 1.68-7.27])., Conclusions: We demonstrated in this meta-analysis an excess risk of livedo in aPL-positive SLE patients compared to aPL-negative patients. For daily practice, in patients with SLE, livedo associated with aPL could correspond to a peculiar group of patients with small vessel disease. Livedo could be a good candidate for inclusion in future classification criteria for antiphospholipid syndrome.- Published
- 2022
- Full Text
- View/download PDF
28. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis.
- Author
-
Domingues V, Chock EY, Dufrost V, Risse J, Seshan SV, Barbhaiya M, Sartelet H, Erkan D, Wahl D, and Zuily S
- Subjects
- Antibodies, Anticardiolipin, Antibodies, Antiphospholipid, Cross-Sectional Studies, Glycoproteins, Humans, Immunoglobulin G, Kidney pathology, Lupus Coagulation Inhibitor, Antiphospholipid Syndrome, Lupus Erythematosus, Systemic, Lupus Nephritis complications, Lupus Nephritis pathology
- Abstract
Background: Microvascular renal lesions have been described in patients with antiphospholipid antibodies (aPL), however their association with aPL is inconsistent among studies. Therefore, our objective was to investigate associations between microvascular renal lesions and aPL among systemic lupus erythematosus (SLE) patients., Methods: Studies were selected if they included SLE patients with and without aPL positivity with a description of kidney biopsy identifying acute and/or chronic microvascular renal lesions as well as lupus nephritis. Data sources were Pubmed, Embase, Cochrane Library, hand search, congress abstracts, and reference lists of studies, without language restrictions. Risk estimates were independently extracted by 2 investigators. Pooled effect estimates were obtained by using the Mantel-Haenszel method (random effects)., Results: Of 1860 identified records obtained between 1991 and 2021, 35 published studies (10 cohorts, 7 case-control, 18 cross-sectional) met inclusion criteria, including 3035 SLE patients according to American College of Rheumatology criteria and 454 cases of microvascular renal lesions. Frequency of microvascular renal lesions in aPL-positive vs. aPL-negative SLE patients was 31.3% vs. 10.4%, respectively. The overall pooled odds ratios (OR) for microvascular renal lesions in aPL-positive vs. aPL-negative SLE patients was 3.03 (95% confidence interval [CI], 2.25-4.09). The risk of microvascular renal lesions was the highest for lupus anticoagulant (OR = 4.84 [95% CI, 2.93 to 8.02]) and IgG anticardiolipin antibodies (OR = 3.12 [95% CI,1.08-9.02]) while the association with anti-β
2 -glycoprotein I antibodies (OR = 1.88 [95% CI, 0.25-14.14]) did not reach statistical significance. Furthermore, aPL were not associated with any classes of lupus nephritis., Conclusion: In SLE patients, aPL-positivity is associated with a significant 3- to 5-fold increased risk for specific microvascular renal lesions. This risk is mainly driven by lupus anticoagulant and IgG anticardiolipin antibodies. Our results support the inclusion of microvascular renal lesions as new criteria for definite antiphospholipid syndrome., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 Elsevier B.V. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
29. A new pro-thrombotic mechanism of neutrophil extracellular traps in antiphospholipid syndrome: impact on activated protein C resistance.
- Author
-
Foret T, Dufrost V, Salomon du Mont L, Costa P, Lakomy C, Lagrange J, Lacolley P, Regnault V, Zuily S, and Wahl D
- Subjects
- Cross-Sectional Studies, Humans, Activated Protein C Resistance, Antiphospholipid Syndrome, Extracellular Traps metabolism, Thrombosis etiology
- Abstract
Objectives: In APS, precise evaluation of thrombotic risk is a major challenge. Different players, such as activated protein C (APC) resistance or neutrophil extracellular traps (NETs) contribute to the risk of thrombosis. Nevertheless, no study has investigated the interaction between these actors. The main objective of this study was to investigate the relation between NETs and APC resistance., Methods: We designed a cross-sectional study including APS/antiphospholipid antibodies (aPL) patients and patients with autoimmune diseases (AID). We performed thrombin generation tests without and with APC to determine APC resistance. To evaluate circulating NETs, we measured plasma levels of MPO-DNA complexes and cell-free DNA with ELISA., Results: We recruited 117 patients with definite APS/aPL or AID. We found a positive correlation between NETs and APC resistance, in APS patients and specifically in patients with high thrombotic risk, displaying LA or positivity of all three aPL tests (triple+), or anti-domain I IgG (aDI+). All these patient subgroups had increased NETs concentrations and APC resistance. As the risk profile for thrombosis increased, the relationship between NETs and APC resistance was stronger., Conclusion: We have shown that NETs participate in the hypercoagulable state of APS patients by contributing to APC resistance, in particular in high-risk patients. In these most at-risk patients, a targeted action on NETs could reduce APC resistance and constitute a new therapeutic approach in the treatment of APS patients in addition to antithrombotic therapy., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
30. Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients.
- Author
-
Mekinian A, Biard L, Dagna L, Novikov P, Salvarani C, Espitia O, Sciascia S, Michaud M, Lambert M, Hernández-Rodríguez J, Schleinitz N, Awisat A, Puéchal X, Aouba A, Munoz Pons H, Smitienko I, Gaultier JB, Le Mouel E, Benhamou Y, Perlat A, Jego P, Goulenok T, Sacre K, Lioger B, Hassold N, Broner J, Dufrost V, Sene T, Seguier J, Maurier F, Berthier S, Belot A, Frikha F, Denis G, Audemard-Verger A, Kone Pault I, Humbert S, Woaye-Hune P, Tomelleri A, Baldissera E, Kuwana M, Lo Gullo A, Gaches F, Zeminsky P, Galli E, Alvarado M, Boiardi L, Muratore F, Vautier M, Campochiaro C, Moiseev S, Cacoub P, Fain O, and Saadoun D
- Subjects
- Adult, Antibodies, Monoclonal, Humanized, Female, Humans, Recurrence, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor Inhibitors, Takayasu Arteritis complications, Takayasu Arteritis drug therapy, Tumor Necrosis Factor-alpha
- Abstract
Objective: To assess the safety and the efficacy of TNF-α antagonists and tocilizumab in patients with Takayasu arteritis (TAK)., Methods: A total of 209 patients with TAK [median age 29 years (interquartile range 7-62)], 186 (89%) females] were included. They received either TNF-α antagonists [n = 132 (63%) with 172 lines; infliximab (n = 109), adalimumab (n = 45), golimumab (n = 8), certolizumab (n = 6) and etanercept (n = 5)] or tocilizumab [n = 77 (37%) with 121 lines; i.v. and s.c. in 95 and 26 cases, respectively]., Results: A complete response at 6 months was evidenced in 101/152 (66%) patients on TNF-α antagonists and 75/107 (70%) patients on tocilizumab. Age ≥30 years [odds ratio 2.09 (95% CI 1.09, 3.99)] was associated with complete response, whereas vascular signs [OR 0.26 (95% CI 0.1, 0.65)], baseline prednisone ≥20 mg/day [OR 0.51 (95% CI 0.28, 0.93)] were negatively associated with the complete response to TNF-α antagonists or tocilizumab. During a median follow-up of 36 months, 103 relapses were noted. Supra-aortic branches and thoracic aorta involvement [HR 2.44 (95% CI 1.06, 5.65) and 3.66 (1.18, 11.4), respectively] and systemic signs at baseline [HR 2.01 (95% CI 1.30, 3.11)] were significantly associated with relapse. The cumulative incidence of treatment discontinuation and relapse were similar in TNF-α antagonists and tocilizumab. Fifty-eight (20%) adverse effects occurred on biologic targeted therapies [37 (21%) on TNF-α antagonists and 21 (17%) on tocilizumab (P = 0.4), respectively]., Conclusion: This large multicentre study shows high efficacy of biologic targeted treatments in refractory TAK. Efficacy, relapse and drug retention rate were equivalent with TNF-α antagonists and tocilizumab., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
31. Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: A systematic review and meta-analysis.
- Author
-
Bernardoff I, Picq A, Loiseau P, Foret T, Dufrost V, Moulinet T, Unlu O, Erkan D, Wahl D, and Zuily S
- Subjects
- Antibodies, Antiphospholipid, Humans, Lupus Coagulation Inhibitor, Anemia, Hemolytic, Autoimmune complications, Anemia, Hemolytic, Autoimmune epidemiology, Antiphospholipid Syndrome, Lupus Erythematosus, Systemic complications
- Abstract
Background: According to criteria for the classification of Systemic Lupus Erythematosus (SLE), autoimmune hemolytic anemia is one of the disease-defining hematologic disorders together with thrombocytopenia. Since the recognition of Antiphospholipid Syndrome (APS), hemolytic anemia was frequently reported but several studies yielded contradictory results on the association between antiphospholipid antibodies (aPL) and hemolytic anemia. Therefore, we evaluated the association of aPL and autoimmune hemolytic anemia in SLE patients by conducting a systematic review and meta-analysis of available literature., Methods: MEDLINE, EMBASE, Cochrane Library, congress abstracts, and reference lists of eligible studies were searched from 1987 to 2020. Studies were selected if they included SLE patients with descriptions of exposure to aPL and occurrence of hemolytic anemia. Three reviewers extracted study characteristics and association data from published reports. Risk estimates were pooled using random effects models and sensitivity analyses. We followed the PRISMA guidelines for all stages of the meta-analysis (Supplemental Table). PROSPERO registration number: CRD42015027376., Results: From 3555 articles identified, 38 studies met inclusion criteria and included 8286 SLE patients. 20.5% of aPL-positive SLE patients had hemolytic anemia compared to 8.7% in aPL-negative SLE patients. The overall pooled Odds Ratio (OR) for hemolytic anemia in aPL positive patients was 2.83 (95% CI; 2.12-3.79). Among aPL subtypes, the risk of hemolytic anemia was highest for lupus anticoagulant (OR = 3.37 [95% CI; 2.26-5.04]) and, antiβ
2 Glycoprotein I antibodies (OR = 3.21 [95% CI; 1.54-6.72]), especially IgM antiβ2 Glycoprotein I (OR = 3.01 [95% CI; 1.26, 7.24])., Conclusions: The occurrence of hemolytic anemia was strongly associated with presence of aPL in SLE patients. Interestingly, IgM isotypes indicate an increased risk of hemolytic anemia in SLE., (Copyright © 2021 Elsevier B.V. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
32. A Giant Abdominal Aortic Aneurysm Revealing a Marfan Syndrome With a New FBN1 Mutation.
- Author
-
Filippetti L, Dufrost V, Busby-Venner H, Hanna N, Arnaud P, Settembre N, Mandry D, Malikov S, Wahl D, and Zuily S
- Subjects
- Adult, Aortic Aneurysm, Abdominal diagnosis, DNA Mutational Analysis, Fibrillin-1 metabolism, Follow-Up Studies, Humans, Imaging, Three-Dimensional, Male, Marfan Syndrome diagnosis, Marfan Syndrome genetics, Patient Acuity, Time Factors, Tomography, X-Ray Computed, Aorta, Abdominal diagnostic imaging, Aortic Aneurysm, Abdominal etiology, DNA genetics, Fibrillin-1 genetics, Marfan Syndrome complications, Mutation
- Abstract
Marfan syndrome is a connective tissue disease that rarely presents first with peripheral aortic aneurysms. We highlight the case of a young man with Marfan syndrome presenting with an abdominal aortic aneurysm due to a heterozygous fibrillin-1 gene mutation., (Copyright © 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
33. Ophthalmologic manifestations in patients with antiphospholipid antibodies: Beware of iatrogenic complications.
- Author
-
Menet J, Agrinier N, Dufrost V, Conart JB, Wahl D, Duprez KA, and Zuily S
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Glucocorticoids adverse effects, Glucocorticoids therapeutic use, Humans, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic immunology, Male, Middle Aged, Retinal Vein Occlusion etiology, Retinal Vein Occlusion immunology, Antibodies, Antiphospholipid adverse effects, Antibodies, Antiphospholipid immunology, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome drug therapy, Antiphospholipid Syndrome immunology, Eye Diseases chemically induced, Eye Diseases etiology, Eye Diseases immunology, Iatrogenic Disease
- Abstract
Background: Antiphospholipid syndrome (APS) is characterized by several clinical manifestations such as venous and arterial thrombosis associated with persistent antiphospholipid antibodies (aPL). Several studies confirmed that retinal vein occlusion was the most common APS ocular manifestation. The purpose of this study was to identify ophthalmologic manifestations in a homogeneous cohort of well-defined persistently aPL-positive patients and to determine variables associated with these manifestations., Methods: APL-positive patients were selected from two research programs. All ophthalmologic manifestations including those related to APS were recorded., Results: A total of 117 patients were included and 10 of them had APS-related ophthalmologic manifestations (glaucoma, hydroxychloroquine-related maculopathy, anterior acute uveitis, anterior ischemic optic neuropathy). Systemic Lupus Erythematosus (SLE) (OR = 3.4[95%CI; 0.9-12.7), corticosteroids (OR = 9.0 [95%CI; 2.2-37.7]) and aPL-related nephropathy (OR = 7.1 [95%CI; 1.7-30.0]) were significatively associated with the risk of APS-related ophthalmologic manifestations., Conclusion: Most of ocular manifestations in this study were iatrogenic related to corticosteroids or hydroxychloroquine. Patients with SLE, small vessel thrombosis in general, or with aPL-related nephropathy in particular, seemed at higher risk to develop APS-related ophthalmologic manifestations thus deserving adequate monitoring.
- Published
- 2021
- Full Text
- View/download PDF
34. Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?
- Author
-
Foret T, Dufrost V, Salomon Du Mont L, Costa P, Lefevre B, Lacolley P, Regnault V, Zuily S, and Wahl D
- Subjects
- Antibodies, Anticardiolipin immunology, C-Reactive Protein immunology, COVID-19 blood, COVID-19 complications, Fibrin Fibrinogen Degradation Products metabolism, Fibrinogen metabolism, Humans, Immunoglobulin A immunology, Immunoglobulin G immunology, Immunoglobulin M immunology, Lupus Coagulation Inhibitor immunology, SARS-CoV-2, Severity of Illness Index, Thrombosis blood, Thrombosis etiology, beta 2-Glycoprotein I immunology, Antibodies, Antiphospholipid immunology, COVID-19 immunology, Thrombosis immunology
- Abstract
Purpose of Review: COVID-19 patients have a procoagulant state with a high prevalence of thrombotic events. The hypothesis of an involvement of antiphospholipid antibodies (aPL) has been suggested by several reports. Here, we reviewed 48 studies investigating aPL in COVID-19 patients., Recent Findings: Prevalence of Lupus Anticoagulant (LA) ranged from 35% to 92% in ICU patients. Anti-cardiolipin (aCL) IgG and IgM were found in up to 52% and up to 40% of patients respectively. Anti-β
2 -glycoprotein I (aβ2 -GPI) IgG and IgM were found in up to 39% and up to 34% of patients respectively. Between 1% and 12% of patients had a triple positive aPL profile. There was a high prevalence of aβ2 -GPI and aCL IgA isotype. Two cohort studies found few persistent LA but more persistent solid phase assay aPL over time. aPL determination and their potential role is a real challenge for the treatment of this disease.- Published
- 2021
- Full Text
- View/download PDF
35. Vascular manifestations and kyphoscoliosis due to a novel mutation of PLOD1 gene.
- Author
-
Zieminski P, Risse J, Legrand A, Dufrost V, Bal L, Settembre N, Malikov S, Jeunemaitre X, Wahl D, and Zuily S
- Subjects
- Adult, Female, Humans, Mutation, Ehlers-Danlos Syndrome genetics, Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase genetics
- Published
- 2021
- Full Text
- View/download PDF
36. Risk of thrombosis, pregnancy morbidity or death in antiphospholipid antibodies positive patients with or without thrombocytopenia.
- Author
-
Moulinet T, Dufrost V, Clerc-Urmès I, Wahl D, and Zuily S
- Subjects
- Antibodies, Antiphospholipid, Female, Humans, Morbidity, Pregnancy, Antiphospholipid Syndrome complications, Lupus Erythematosus, Systemic, Thrombocytopenia, Thrombosis
- Published
- 2021
- Full Text
- View/download PDF
37. Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials.
- Author
-
Dufrost V, Wahl D, and Zuily S
- Subjects
- Administration, Oral, Humans, Randomized Controlled Trials as Topic, Thrombosis, Warfarin adverse effects, Anticoagulants adverse effects, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome drug therapy, Venous Thromboembolism drug therapy
- Abstract
Background: The gold standard for secondary thromboprophylaxis in APS is long term anticoagulation with vitamin K antagonists (VKAs). Because of their widespread use and potential advantages of directs oral anticoagulants (DOACs) over VKAs, they have been prescribed in APS without definitive evidence of their safety and efficacy in this context. Recent specific randomized controlled trials (RCT) in APS and results from pivotal RCTs comparing DOACs vs VKAs are now available. Their results are conflicting but these studies have been conducted in different APS populations., Purpose of Review: To summarize available data from RCT and determine risks of recurrent thrombosis and bleeding., Results: Four studies were included and 23 and 10 thrombotic events were recorded among 282 and 294 APS patients treated with DOACs and warfarin respectively. Overall recurrent thrombotic events were not significantly increased during DOACs treatment (OR = 2.22 [95% CI, 0.58-8.43]) compared to VKAs. However, when different types of thrombosis were analyzed separately, there was an increased risk of recurrent arterial thrombosis (5.17 [95% CI, 1.57-17.04]) with DOACs compared to warfarin but no significant higher risk of venous thrombosis (OR 0.69 [95% CI, 0.23-2.06). No increased risk of bleeding was found., In Conclusion: In APS patients treated with DOACs compared to those treated with warfarin, no evidence of a higher risk of recurrent venous thromboembolism was found however there was a significantly increased risk of recurrent arterial thrombosis. Moreover risk of recurrent arterial thrombosis tended to be more frequent in patients with a history of arterial thrombosis. These results are in line with international guidelines which recommend not to use DOACs in APS patients with a history of arterial thrombosis but raise the question of the efficacy of DOACs to prevent venous thrombosis in a subset of APS patients without a history of arterial thrombosis., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
38. Anti-Domain I β2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study.
- Author
-
Zuily S, de Laat B, Guillemin F, Kelchtermans H, Magy-Bertrand N, Desmurs-Clavel H, Lambert M, Poindron V, de Maistre E, Dufrost V, Risse J, Shums Z, Norman GL, de Groot PG, Lacolley P, Lecompte T, Regnault V, and Wahl D
- Subjects
- Cohort Studies, Cross-Sectional Studies, Female, Humans, Prospective Studies, beta 2-Glycoprotein I, Activated Protein C Resistance complications, Activated Protein C Resistance diagnosis, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome diagnosis, Thrombosis
- Abstract
Background: Antibodies binding to domain I of β2-glycoprotein I (aDI) and activated protein C (APC) resistance are associated with an increased risk of thrombosis in cross-sectional studies. The objective of this study was to assess their predictive value for future thromboembolic events in patients with antiphospholipid antibodies (aPL) or antiphospholipid syndrome., Methods: This prospective multicenter cohort study included consecutive patients with aPL or systemic lupus erythematosus. We followed 137 patients (43.5 ± 15.4 year old; 107 women) for a mean duration of 43.1 ± 20.7 months., Results: We detected aDI IgG antibodies by ELISA in 21 patients. An APC sensitivity ratio (APCsr) was determined using a thrombin generation-based test. The APCsr was higher in patients with anti-domain I antibodies demonstrating APC resistance (0.75 ± 0.13 vs 0.48 ± 0.20, P < 0.0001). In univariate analysis, the hazard ratio (HR) for thrombosis over time was higher in patients with aDI IgG (3.31 [95% CI, 1.15-9.52]; P = 0.03) and patients with higher APC resistance (APCsr >95th percentile; HR, 6.07 [95% CI, 1.69-21.87]; P = 0.006). A sensitivity analysis showed an increased risk of higher aDI IgG levels up to HR 5.61 (95% CI, 1.93-16.31; P = 0.01). In multivariate analysis, aDI IgG (HR, 3.90 [95% CI, 1.33-11.46]; P = 0.01) and APC resistance (HR, 4.98 [95% CI, 1.36-18.28]; P = 0.02) remained significant predictors of thrombosis over time., Conclusions: Our study shows that novel tests for antibodies recognizing domain I of β2-glycoprotein I and functional tests identifying APC resistance are significant predictors of thrombosis over time and may be useful for risk stratification., (© American Association for Clinical Chemistry 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
39. [Arterial and venous thrombosis in patients with COVID-19].
- Author
-
Zuily S, Dufrost V, and Wahl D
- Published
- 2020
- Full Text
- View/download PDF
40. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
- Author
-
Zuily S, Cohen H, Isenberg D, Woller SC, Crowther M, Dufrost V, Wahl D, Doré CJ, Cuker A, Carrier M, Pengo V, and Devreese KMJ
- Subjects
- Anticoagulants therapeutic use, Humans, Lupus Coagulation Inhibitor, Reference Standards, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome diagnosis, Antiphospholipid Syndrome drug therapy, Thrombosis drug therapy, Thrombosis prevention & control
- Abstract
Clarity and guidance is required with regard to the use of direct oral anticoagulants in antiphospholipid syndrome (APS) patients, within the confines of the recent European Medicines Agency recommendations, discrepant recommendations in other international guidelines and the limited evidence base. To address this, the Lupus Anticoagulant/Antiphospholipid Antibodies Scientific and Standardization Committee (SSC) chair and co-chairs together with SSC Control of Anticoagulation members propose guidance for healthcare professionals to help them manage APS patients. Uncertainty in this field will be addressed. This guidance will also serve as a call and focus for research., (© 2020 International Society on Thrombosis and Haemostasis.)
- Published
- 2020
- Full Text
- View/download PDF
41. New Insights into the Use of Direct Oral Anticoagulants in Non-high Risk Thrombotic APS Patients: Literature Review and Subgroup Analysis from a Meta-analysis.
- Author
-
Dufrost V, Darnige L, Reshetnyak T, Vorobyeva M, Jiang X, Yan XX, Gerotziafas G, Jing ZC, Elalamy I, Wahl D, and Zuily S
- Subjects
- Humans, Anticoagulants adverse effects, Anticoagulants therapeutic use, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome drug therapy, Thrombosis chemically induced, Thrombosis prevention & control
- Abstract
Purpose of Review: The efficacy of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS) is discussed. Results from randomized controlled trials are available. It has been stated that a history of arterial thrombosis and triple positivity was associated with a higher risk of thrombosis in APS patients treated with DOACs. However, their efficacy in non-high-risk APS patients with isolated venous manifestations is unsolved. Therefore, we performed a sub-group analysis of a previously published meta-analysis after the exclusion of patients with triple positivity and those with history of arterial or small vessel thrombosis., Recent Findings: We identified 290 APS patients with previous isolated venous event treated with DOACs; among them, 25 (8.6%) patients experienced a recurrent thrombosis in comparison to 16% in the original cohort. We found that the rate of recurrent thrombosis is lower in APS patients with isolated venous manifestations than in overall APS patients including high-risk patients. Research about DOAC use in non-high-risk APS patients needs to be continued.
- Published
- 2020
- Full Text
- View/download PDF
42. Health-Related Quality of Life in Antiphospholipid Syndrome: Current Knowledge and Future Perspectives.
- Author
-
Desnoyers M, Dufrost V, Wahl D, and Zuily S
- Subjects
- Humans, Antiphospholipid Syndrome complications, Lupus Erythematosus, Systemic complications, Quality of Life, Thrombosis etiology
- Abstract
Purpose of Review: Antiphospholipid syndrome (APS) is a chronic autoimmune disease that can be seen as a burden, with consequences on patients' daily life. Health has traditionally been measured using measures of morbidity or mortality. Health-related quality of life (HRQoL) is a concept that includes quality of life through physical, mental, and social domains. As in other autoimmune diseases, HRQoL has been investigated in patients with APS. Here, we provide a comprehensive review of the current knowledge of the assessment of HRQoL in APS., Recent Findings: APS patients have an impaired HRQoL compared with the general population. The presence of systemic lupus erythematosus (SLE) in APS patients is associated with a worse HRQoL than in patients without SLE. Several determinants of HRQoL impairment in APS have been identified: age, gender, history of arterial thrombosis, organ damage, lack of social support and treatments. This review highlights the negative impact of thrombosis on APS patients' HRQoL that should not be neglected. Besides, there is a need for a better strategy of communication and information, in order to improve HRQoL in APS.
- Published
- 2020
- Full Text
- View/download PDF
43. Corrigendum to "Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis" [AUTREV 18-11 (2019) 102395].
- Author
-
Chock YP, Moulinet T, Dufrost V, Erkan D, Wahl D, and Zuily S
- Published
- 2020
- Full Text
- View/download PDF
44. Direct Oral Anticoagulants in Antiphospholipid Syndrome: Too Early or Too Late?
- Author
-
Wahl D and Dufrost V
- Subjects
- Anticoagulants, Humans, Vitamin K, Warfarin, Antiphospholipid Syndrome, Rivaroxaban
- Published
- 2019
- Full Text
- View/download PDF
45. Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis.
- Author
-
Chock YP, Moulinet T, Dufrost V, Erkan D, Wahl D, and Zuily S
- Subjects
- Case-Control Studies, Cohort Studies, Cross-Sectional Studies, Humans, Lupus Erythematosus, Systemic immunology, Risk Factors, Thrombocytopenia immunology, Antibodies, Antiphospholipid immunology, Lupus Erythematosus, Systemic epidemiology, Thrombocytopenia epidemiology
- Abstract
Background: According to criteria for the classification of Systemic Lupus Erythematosus (SLE), thrombocytopenia is one of the disease-defining hematologic disorders. Since the recognition of Antiphospholipid Syndrome (APS), thrombocytopenia was frequently reported but several studies yielded contradictory results on the association between aPL-positivity and thrombocytopenia., Methods: We evaluated the role of antiphospholipid antibodies (aPL) and different aPL profiles on the risk of thrombocytopenia in SLE patients by conducting a systematic review and meta-analysis of available literature from 1987 to 2018. MEDLINE, EMBASE, Cochrane Library, congress abstracts, and reference lists of eligible studies were searched. Studies were selected if they included SLE patients with descriptions of the exposure to aPL and the outcomes (thrombocytopenia). Two reviewers extracted study characteristics and outcome data from published reports. Estimates were pooled using random effects models and sensitivity analyses. We followed the PRISMA guidelines for all stages of the meta-analysis. PROSPERO registration number: CRD42015027378., Results: From 3278 articles identified, 53 studies met inclusion criteria amounting to 9019 SLE patients. Twenty-nine percent of aPL-positive SLE patients had thrombocytopenia compared to 15.1% in aPL-negative SLE patients. The overall pooled Odds Ratio (OR) for thrombocytopenia in aPL positive patients was 2.48 (95% CI; 2.10-2.93). Among aPL subtypes, the risk of thrombocytopenia was highest for lupus anticoagulant (OR = 3.56 [95% CI, 2.57-5.25]), IgM anti-β
2 -GP1(OR = 2.87 [95% CI; 2.57-5.25]), IgG and IgM anticardiolipin antibodies (OR = 1.87 [95% CI; 1.52-2.31] and OR = 1.73 [95% CI; 1.36-2.19] respectively)., Conclusions: The occurrence of thrombocytopenia was strongly determined by various aPL profiles in SLE patients. While the association between IgM antibodies and other APS manifestations including thrombosis is debated, IgM isotypes are helpful in the risk stratification of thrombocytopenia in SLE., (Copyright © 2019 Elsevier B.V. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
46. Impact of antiphospholipid syndrome iBook on medical students' improvement of knowledge: An international randomized controlled study.
- Author
-
Zuily S, Phialy L, Sevim E, Germain E, Unlu O, Dufrost V, Risse J, Clerc-Urmès I, Baumann C, Berman JR, Lockshin MD, Wahl D, and Erkan D
- Abstract
Objective: iBook on Antiphospholipid Syndrome (APS) did not exist before our work, and hence the utility of an Apple iBook as a teaching method in APS for medical students has never been assessed. Our objective was to evaluate medical students' improvement of knowledge and satisfaction with an interactive APS iBook, in comparison with conventional teaching methods., Methods: An iBook designer with the guidance of a medical team developed the APS iBook in both French and English. Second-year medical students, naïve of APS knowledge, were enrolled from two institutions. For the "teaching intervention", participants were randomly assigned to three groups: a) APS iBook with interactive capability; b) printed copy of the APS iBook material; and c) classroom lecture presentation of the APS iBook material by a physician-scientist experienced in APS. The participants filled a standardized medical questionnaire about APS before and after teaching interventions to determine the relative change of knowledge. Participants were asked to fill out a standardized satisfaction survey. After 20 weeks of the intervention, recall capability of students was tested., Results: A total of 233 second-year medical students were enrolled (iBook group: 73; print group: 79, and lecture group: 81). Relative change of knowledge was not different between the iBook group and the printed material group; additionally, it was significantly higher in the lecture group than the two other methods. Satisfaction was significantly higher in both the lecture and the iBook groups than the print group, on several dimensions including overall quantitative satisfaction, subjective enhanced knowledge, interactivity, quality of content, comprehensibility, and pleasure of learning. Recall capability of students (n=109, 47%) was not significantly different among groups., Conclusion: The APS iBook is as effective as printed material in improving medical student's knowledge, although a classroom lecture was the most effective method when compared to self-learning methods. Among self-learning methods, medical students are more satisfied with the APS iBook, whereas the recall capability was not different among groups. These results suggest that the APS iBook will help medical students in their curriculum and increase the awareness of APS among the community.
- Published
- 2019
- Full Text
- View/download PDF
47. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: A systematic review and meta-analysis: Comment.
- Author
-
Dufrost V, Wahl D, and Zuily S
- Subjects
- Anticoagulants, Humans, Thrombophilia, Venous Thromboembolism
- Published
- 2019
- Full Text
- View/download PDF
48. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.
- Author
-
Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan XX, Salta S, Gerotziafas G, Jing ZC, Elalamy I, Wahl D, and Zuily S
- Subjects
- Anticoagulants administration & dosage, Antiphospholipid Syndrome physiopathology, Cross-Sectional Studies, Humans, Randomized Controlled Trials as Topic, Recurrence, Venous Thromboembolism drug therapy, Warfarin therapeutic use, Anticoagulants adverse effects, Antiphospholipid Syndrome drug therapy, Thrombosis chemically induced
- Abstract
Background: Direct oral anticoagulants (DOACs) are widely used for secondary prevention of venous thromboembolism (VTE) but their clinical efficacy and safety are not established in Antiphospholipid Syndrome (APS) patients. There is only one randomized controlled trial published while others are still ongoing. Many non-randomized studies have been published in this field with conflicting opinions., Purpose of Review: We conducted a systematic review using MEDLINE, EMBASE and Cochrane databases from 2000 until March 2018 regarding APS patients treated with DOACs. We performed a patient-level data meta-analysis to a) estimate the prevalence of recurrent thrombosis in APS patients treated with DOACs in the literature, and b) identify variables associated with recurrent thrombosis., Results: We identified 47 studies corresponding to 447 APS patients treated with DOACs. Three commercially available DOACs were analyzed: rivaroxaban (n = 290), dabigatran etexilate (n = 144) and apixaban (n = 13). A total of 73 out of 447 patients (16%) experienced a recurrent thrombosis while on DOACs with a mean duration until thrombosis of 12.5 months. Rates of recurrent thromboses were 16.9% and 15% in APS patients receiving either anti-Xa inhibitors or dabigatran respectively. Triple positivity (positivity for all three antiphospholipid antibodies) was associated with a four-fold increased risk of recurrent thrombosis (56% vs 23%; OR = 4.3 [95%CI; 2.3-7.7], p < 0.0001) as well as a higher number of clinical criteria for APS classification. In patients treated with anti-Xa inhibitors, history of arterial thrombosis was associated with a higher risk of recurrent thrombosis (32% vs 14%; OR = 2.8 [95%CI; 1.4-5.7], p = 0.006). In conclusion, DOACs are not effective in all APS patients and should not be used routinely in these patients. Randomized controlled trials assessing clinical efficacy and safety as primary endpoints are underway. In the meantime, a registry of APS patients on DOACs could be proposed to establish in which APS subgroups DOACs would be a safe alternative to warfarin., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
49. Comment on: Failure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome: reply.
- Author
-
Dufrost V, Risse J, Wahl D, and Zuily S
- Subjects
- Anticoagulants, Factor Xa Inhibitors, Humans, Thrombosis, Antiphospholipid Syndrome, Rivaroxaban
- Published
- 2018
- Full Text
- View/download PDF
50. Unexpected Cause of Bleeding.
- Author
-
Dufrost V, Risse J, Malgras A, Barraud H, Jaussaud R, Zuily S, and Wahl D
- Subjects
- Ascorbic Acid therapeutic use, Diagnosis, Differential, Humans, Leg blood supply, Male, Middle Aged, Scurvy drug therapy, Hematoma diagnosis, Hematoma etiology, Scurvy complications, Scurvy diagnosis
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.